WFRF:(Gelber Richard D)
Search: WFRF:(Gelber Richard D) > Adjuvant! Online es...
- 2 of 23
- Previous record
- Next record
- To hitlist
Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer
- Paridaens, Robert J (author)
- Gelber, Shari (author)
- Cole, Bernard F (author)
- show more...
- Gelber, Richard D (author)
- Thürlimann, Beat (author)
- Price, Karen N (author)
- Crivellari, Diana (author)
- Coates, Alan S (author)
- Goldhirsch, Aron (author)
- show less...
- (creator_code:org_t)
- 2010-02-27
- 2010
- English.
- In: Breast cancer research and treatment. - : Springer Science and Business Media LLC. - 1573-7217 .- 0167-6806. ; 123:1, s. 303-310
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- Adjuvant! Online (Adjuvant!) is a user-friendly, web-based tool that provides estimates of adjuvant therapy outcomes for individual patients. While reliable evidence underpins estimates for most patient cohorts, there is a paucity of data on the effect of adding chemotherapy to complete estrogen blockade for premenopausal women with estrogen-receptor positive breast cancer. International Breast Cancer Study Group (IBCSG) Trial 11-93 enrolled 174 premenopausal women with estrogen-receptor positive, node-positive breast cancer. Among these patients, 55% had one positive axillary lymph node and 97% had three or fewer positive nodes. Patients were randomized to receive ovarian function suppression plus 5 years of tamoxifen with or without anthracycline-based chemotherapy. Estimated hazard rates and corresponding 10-year relapse-free survival percentages obtained from Trial 11-93 data were compared with those predicted using Adjuvant!. The 10-year relapse-free survival percentages predicted from Adjuvant! were 64.4% (95% CI, 61.9-67.2%) for endocrine therapy alone and 74.9% (95% CI, 73.1-76.8%) for chemoendocrine therapy. By contrast, these estimates in Trial 11-93 were 76.4% (95% CI, 65.8-84.0%) for endocrine therapy alone and 74.9% (95% CI, 64.5-82.7%) for chemoendocrine therapy. The Adjuvant! estimate for the endocrine-alone control group is lower than that observed in Trial 11-93 (P = 0.03), while the estimates for the two chemoendocrine therapy groups are similar. Adjuvant! appears to underestimate the effectiveness of adjuvant endocrine therapy alone for premenopausal women with endocrine responsive breast cancer, thus overestimating the added benefit, if any, from chemotherapy for this patient population.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Keyword
- Adjuvant!© Online
- Estrogen receptor
- Premenopausal
- Chemotherapy
- Endocrine therapy
- International Breast Cancer Study Group
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
- Breast cancer research and treatment (Search for host publication in LIBRIS)
To the university's database
- 2 of 23
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Paridaens, Rober ...
- Gelber, Shari
- Cole, Bernard F
- Gelber, Richard ...
- Thürlimann, Beat
- Price, Karen N
- show more...
- Holmberg, Stig B ...
- Crivellari, Dian ...
- Coates, Alan S
- Goldhirsch, Aron
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Cancer and Oncol ...
- Articles in the publication
- Breast cancer re ...
- By the university
- University of Gothenburg
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
